// For flags

CVE-2017-17678

 

Severity Score

6.1
*CVSS v3.1

Exploit Likelihood

*EPSS

Affected Versions

*CPE

Public Exploits

0
*Multiple Sources

Exploited in Wild

-
*KEV

Decision

-
*SSVC
Descriptions

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

BMC Remedy Mid Tier versión 9.1SP3, está afectado por una vulnerabilidad de tipo cross-site scripting (XSS). Se detectó una vulnerabilidad de tipo cross-site scripting basada en DOM en una utilidad heredada

*Credits: N/A
CVSS Scores
Attack Vector
Network
Attack Complexity
Low
Privileges Required
None
User Interaction
Required
Scope
Changed
Confidentiality
Low
Integrity
Low
Availability
None
Attack Vector
Network
Attack Complexity
Medium
Authentication
None
Confidentiality
None
Integrity
Partial
Availability
None
* Common Vulnerability Scoring System
SSVC
  • Decision:-
Exploitation
-
Automatable
-
Tech. Impact
-
* Organization's Worst-case Scenario
Timeline
  • 2017-12-13 CVE Reserved
  • 2021-05-19 CVE Published
  • 2024-08-05 CVE Updated
  • 2024-12-17 EPSS Updated
  • ---------- Exploited in Wild
  • ---------- KEV Due Date
  • ---------- First Exploit
CWE
  • CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
CAPEC
Affected Vendors, Products, and Versions
Vendor Product Version Other Status
Vendor Product Version Other Status <-- --> Vendor Product Version Other Status
Bmc
Search vendor "Bmc"
 Remedy Mid-tier
Search vendor "Bmc" for product "Remedy Mid-tier"
 9.1
Search vendor "Bmc" for product "Remedy Mid-tier" and version "9.1"
sp3
Affected